Impact of the Food and Drug Administration's antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings
Impact of the Food and Drug Administration's antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings
复制标题
DOI：
10.1016/j.jalz.2011.08.004
复制
发表时间：
2012-09-01
影响因子：
14
通讯作者：
Kelton, Christina M. L.
中科院分区：
文献类型：
--
作者：
Desai, Vibha C. A.;Heaton, Pamela C.;Kelton, Christina M. L.
背景资料：大多数痴呆患者还患有痴呆症的行为和心理症状，目前还没有食品和药物管理局批准的治疗方法。目的：为了确定食品和药物管理局2005年4月的黑匣子警告是否导致了用于痴呆症行为和心理症状的非典型抗精神病药物处方的减少，以及其他精神药物的处方，包括抗抑郁药，抗焦虑药，抗癫痫药，作为替代品增加。方法：老年痴呆症患者的门诊就诊数据来自2003年至2008年的两次大型全国调查。确定了任何精神药物提及。结果：提及非典型抗精神病药的就诊百分比从12.5%预警下降到11.5%预警后。Postwarning，34.4%的患者没有服用任何研究药物，而26.1% prewarning.Conclusions：警告后，有一个小的下降，在使用非典型抗精神病药物，并没有证据表明其他精神药物的替代品。(C)2012年，阿尔茨海默氏症协会。All rights reserved.
Background: Most patients with dementia also suffer from behavioral and psychological symptoms of dementia, for which there is no Food and Drug Administration-approved treatment.Objectives: To determine whether the Food and Drug Administration's black box warning in April 2005 has led to a decline in prescriptions of atypical antipsychotics for behavioral and psychological symptoms of dementia, as well as whether prescriptions for other psychotropic drugs, including antidepressants, anxiolytics, and antiepileptics, as substitutes, have increased.Methods: Data on outpatient visits by elderly dementia patients were obtained from two large national surveys from 2003 to 2008. Any psychotropic drug mentions were identified. Percentage utilization statistics were calculated.Results: The percentage of visits mentioning an atypical antipsychotic decreased from 12.5% prewarning to 11.5% postwarning. Postwarning, 34.4% of patients were taking none of the study medications, as opposed to 26.1% prewarning.Conclusions: After the warning, there was a small decline in the use of atypical antipsychotics and no evidence of substitution of other psychotropic medications. (C) 2012 The Alzheimer's Association. All rights reserved.